These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 33776702)

  • 1. Detection of Microsatellite Instability via Circulating Tumor DNA and Response to Immunotherapy in Metastatic Castration-Resistant Prostate Cancer: A Case Series.
    Ravindranathan D; Russler GA; Yantorni L; Drusbosky LM; Bilen MA
    Case Rep Oncol; 2021; 14(1):190-196. PubMed ID: 33776702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA.
    Barata P; Agarwal N; Nussenzveig R; Gerendash B; Jaeger E; Hatton W; Ledet E; Lewis B; Layton J; Babiker H; Bryce A; Garje R; Stein C; Kiedrowski L; Saylor P; Sartor O
    J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32788235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long response duration to pembrolizumab in metastatic, castration-resistant prostate cancer with microsatellite instability-high and neuroendocrine differentiation: A case report.
    Yoshida T; Yaegashi H; Toriumi R; Kadomoto S; Iwamoto H; Izumi K; Kadono Y; Ikeda H; Mizokami A
    Front Oncol; 2022; 12():912490. PubMed ID: 36185251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Re-sensitization to pembrolizumab following PSMA-CD3 T-cell redirection therapy with JNJ-081 in a patient with mismatch repair-deficient metastatic castration-resistant prostate cancer: a case report.
    Reed-Perino DE; Lai M; Yu EY; Schweizer MT
    J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37220954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complete Response to Pembrolizumab in a Patient with Castration-Resistant Prostate Cancer with Both BRCA Positivity and a High Frequency of Microsatellite Instability: A Case Report.
    Hirano T; Yonezawa K; Kawahara T; Mizuno N; Hayashi H; Karibe Y; Asano J; Fusayasu S; Makiyama K; Uemura H; Ohta J; Moriyama M
    Case Rep Oncol; 2024; 17(1):852-858. PubMed ID: 39144237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I-Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications.
    Marginean EC; Melosky B
    Arch Pathol Lab Med; 2018 Jan; 142(1):17-25. PubMed ID: 29144791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pembrolizumab for a patient with metastatic castration-resistant prostate cancer with microsatellite instability-high.
    Fujiwara M; Komai Y; Yuasa T; Numao N; Yamamoto S; Fukui I; Yonese J
    IJU Case Rep; 2020 Mar; 3(2):62-64. PubMed ID: 32743472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A real-world experience of pembrolizumab monotherapy in microsatellite instability-high and/or tumor mutation burden-high metastatic castration-resistant prostate cancer: outcome analysis.
    Mosalem O; Tan W; Bryce AH; Dronca RS; Childs DS; Pagliaro LC; Orme JJ; Kase AM
    Prostate Cancer Prostatic Dis; 2024 Feb; ():. PubMed ID: 38341460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dramatic response to pembrolizumab after pseudoprogression in a patient with advanced metastatic castration-resistant prostate cancer.
    Kageyama T; Soga N; Sekito S; Kato S; Ogura Y; Kojima T; Kanai M; Inoue T
    IJU Case Rep; 2022 Nov; 5(6):442-445. PubMed ID: 36341181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A case of microsatellite instability-high clinically advanced castration-resistant prostate cancer showing a remarkable response to pembrolizumab sustained over at least 18 months.
    Shimizu K; Sano T; Mizuno K; Sunada T; Makita N; Hagimoto H; Goto T; Sawada A; Fujimoto M; Ichioka K; Ogawa O; Kobayashi T; Akamatsu S
    Cold Spring Harb Mol Case Stud; 2022 Jun; 8(4):. PubMed ID: 35487690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis.
    Mayrhofer M; De Laere B; Whitington T; Van Oyen P; Ghysel C; Ampe J; Ost P; Demey W; Hoekx L; Schrijvers D; Brouwers B; Lybaert W; Everaert E; De Maeseneer D; Strijbos M; Bols A; Fransis K; Oeyen S; van Dam PJ; Van den Eynden G; Rutten A; Aly M; Nordström T; Van Laere S; Rantalainen M; Rajan P; Egevad L; Ullén A; Yachnin J; Dirix L; Grönberg H; Lindberg J
    Genome Med; 2018 Nov; 10(1):85. PubMed ID: 30458854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microsatellite Instability Predicts Response to Anti-PD1 Immunotherapy in Metastatic Melanoma.
    Roncati L
    Acta Dermatovenerol Croat; 2018 Dec; 26(4):341-343. PubMed ID: 30665488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Larotrectinib in Mismatch-Repair-Deficient TRK Fusion-Positive Metastatic Colon Cancer After Progression on Immunotherapy.
    Kasi PM; Afghan MK; Bellizzi AM; Chan CH
    Cureus; 2022 Jul; 14(7):e26648. PubMed ID: 35815302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Role of Histology-Agnostic Drugs in the Treatment of Metastatic Castration-Resistant Prostate Cancer.
    Iannantuono GM; Torino F; Rosenfeld R; Guerriero S; Carlucci M; Sganga S; Capotondi B; Riondino S; Roselli M
    Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Excellent Response of Microsatellite Instability-High Pancreatic Adenocarcinoma to Pembrolizumab Treatment: The Role of Circulating Tumor DNA Testing.
    Anisetti B; Coston TW; Ahmed AK; Mahadevia HJ; Edgar MA; Starr JS; Babiker HM
    Cureus; 2023 Apr; 15(4):e37239. PubMed ID: 37168199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer.
    Vandekerkhove G; Struss WJ; Annala M; Kallio HML; Khalaf D; Warner EW; Herberts C; Ritch E; Beja K; Loktionova Y; Hurtado-Coll A; Fazli L; So A; Black PC; Nykter M; Tammela T; Chi KN; Gleave ME; Wyatt AW
    Eur Urol; 2019 Apr; 75(4):667-675. PubMed ID: 30638634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence of microsatellite instability-high hepatocellular carcinoma among Japanese patients and response to pembrolizumab.
    Kawaoka T; Ando Y; Yamauchi M; Suehiro Y; Yamaoka K; Kosaka Y; Fuji Y; Uchikawa S; Morio K; Fujino H; Nakahara T; Ono A; Murakami E; Takahashi S; Tsuge M; Hiramatsu A; Imamura M; Chayama K; Aikata H
    Hepatol Res; 2020 Jul; 50(7):885-888. PubMed ID: 32088930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-Accuracy Determination of Microsatellite Instability Compatible with Liquid Biopsies.
    Silveira AB; Bidard FC; Kasperek A; Melaabi S; Tanguy ML; Rodrigues M; Bataillon G; Cabel L; Buecher B; Pierga JY; Proudhon C; Stern MH
    Clin Chem; 2020 Apr; 66(4):606-613. PubMed ID: 32176763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors.
    Marcus L; Lemery SJ; Keegan P; Pazdur R
    Clin Cancer Res; 2019 Jul; 25(13):3753-3758. PubMed ID: 30787022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world data on microsatellite instability status in various unresectable or metastatic solid tumors.
    Akagi K; Oki E; Taniguchi H; Nakatani K; Aoki D; Kuwata T; Yoshino T
    Cancer Sci; 2021 Mar; 112(3):1105-1113. PubMed ID: 33403729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.